SUMATRIPTAN AND NAPROXEN SODIUM Drug Patent Profile

When do Sumatriptan And Naproxen Sodium patents expire, and what generic alternatives are available?

Sumatriptan And Naproxen Sodium is a drug marketed by Aurobindo Pharma Ltd, Rising, and Sun Pharm. and is included in three NDAs.

The generic ingredient in SUMATRIPTAN AND NAPROXEN SODIUM is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.

Summary for SUMATRIPTAN AND NAPROXEN SODIUM

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	3
Clinical Trials:	25
DailyMed Link:	SUMATRIPTAN AND NAPROXEN SODIUM at DailyMed

Recent Clinical Trials for SUMATRIPTAN AND NAPROXEN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Provincial People's Hospital	Phase 3
West China Hospital	Phase 3
The Second Affiliated Hospital of Kunming Medical University	Phase 3

See all SUMATRIPTAN AND NAPROXEN SODIUM clinical trials

Pharmacology for SUMATRIPTAN AND NAPROXEN SODIUM

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

US Patents and Regulatory Information for SUMATRIPTAN AND NAPROXEN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	207457-001	Feb 15, 2018	AB	RX	No	No
Rising	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	090872-001	Sep 4, 2018	AB	RX	No	No
Sun Pharm	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	202803-001	Jul 20, 2018	AB	RX	No	No

Market Dynamics and Financial Trajectory for Sumatriptan and Naproxen Sodium

Last updated: March 15, 2026

What Are the Market Drivers for Sumatriptan and Naproxen Sodium?

The market for sumatriptan and naproxen sodium reflects broader trends in migraine treatment and pain management, driven by rising prevalence, healthcare infrastructure, and pharmaceutical innovation.

Prevalence and Unmet Needs

• Migraine affects approximately 15-20% of the global population, equating to 1.2 billion individuals[1]. Sumatriptan, a triptan, remains a first-line treatment for acute migraine attacks.
• Naproxen sodium is widely used for general pain relief, including tension headaches and musculoskeletal pain, with an estimated global sales exceeding $1.3 billion in 2022[2].

Regulatory and Reimbursement Impact

• The U.S. Food and Drug Administration (FDA) approved novel formulations of sumatriptan, including nasal sprays and autoinjectors, expanding access[3].
• Insurance coverage and reimbursement policies influence prescription rates, particularly in developed markets where medications are reimbursed under national formularies.

Competitive Landscape

• Sumatriptan's patent expired in 2011, prompting generic entries and intensified price competition.
• Several branded and generic naproxen formulations exist, with over-the-counter (OTC) and prescription variants influencing market share.

How Does the Market Size and Revenue Outlook Evolve?

Historical and Projected Market Size

Year	Sumatriptan Market (USD billion)	Naproxen Sodium Market (USD billion)
2022	1.2	1.3
2027	1.6	1.6
Compound Annual Growth Rate (CAGR)	6.2%	4.8%

• The migraine therapeutics segment, including sumatriptan, is projected to grow at a CAGR of 6.2% from 2022 to 2027.
• Over-the-counter (OTC) naproxen formulations contribute significantly to revenue, with OTC sales accounting for roughly 60% of total naproxen sodium sales in developed countries[4].

Price Trends and Margins

• Generic sumatriptan prices declined by approximately 35% post-patent expiry, but innovations such as patch delivery systems have maintained some premium pricing[5].
• Naproxen sodium OTC products have been stable in price, with minor discounts driving volume sales.

What Are the Challenges and Risks Affecting Financial Performance?

Patent and Market Entry

• The expiration of sumatriptan patents led to increased generic competition, compressing profit margins.
• Intellectual property challenges in certain regions inhibit generic market penetration.

Regulatory and Safety Concerns

• Potential adverse effects such as cardiovascular risks with triptans limit prescriber adoption.
• Regulatory scrutiny on NSAIDs related to gastrointestinal and cardiovascular safety impacts patient eligibility and market penetration[6].

Market Saturation and Consumer Preferences

• Consumer shift toward combination therapy and non-pharmacologic alternatives dampens growth prospects.
• OTC availability of naproxen reduces prescription volume, affecting pharmacy revenue streams.

Supply Chain and Manufacturing

• Supply disruptions, especially for active pharmaceutical ingredients (APIs), can impact sales and profitability.
• Regulatory compliance costs for manufacturing strict quality standards elevate operational expenses.

What Is the Future Financial Trajectory?

Revenue Growth Factors

• Development of new formulations (e.g., nasal sprays, auto-injectors) and combination products could boost sales.
• Expanding access in emerging markets with rising healthcare infrastructure supports volume increases.
• Increased awareness of migraine as a chronic condition enhances market penetration for sumatriptan.

Innovation and Pipeline Developments

• Novel triptan compounds with improved safety profiles are in late-stage development, poised to capture market share.
• Extended-release formulations of naproxen may position the drug for chronic pain management, opening up new revenue streams.

Market Penetration Strategies

• Strategic partnerships and licensing agreements with regional players can accelerate market access.
• Direct-to-consumer advertising remains a key tactic for OTC naproxen to sustain volume growth.

Financial Projections Summary

Year	Revenue (USD billion)	Growth Rate	Key Notes
2023	2.9	—	Base year, considering combined sumatriptan and naproxen sales
2025	3.4	8.1%	Growth driven by new formulations and emerging markets
2027	3.8	4.8%	Market stabilization, patent expiries, and competitive pressures

Key Takeaways

• The sumatriptan market faces ongoing commoditization due to patent expiry, but innovation and expanding formulations sustain growth.
• Naproxen sodium benefits from OTC sales, with moderate growth driven by increased consumer awareness and expanded indications.
• Pricing pressures from generics and safety concerns pose risks to profit margins.
• Emerging markets and pipeline products offer future growth avenues.
• Companies focusing on product innovation, strategic partnerships, and expanded access will likely outperform.

FAQs

1. What factors influence the pricing of sumatriptan post-patent expiry?
   Patent expiry leads to generic competition, reducing prices by about 35%, while branded formulations with new delivery systems retain premiums.

2. How does OTC availability affect naproxen sodium sales?
   OTC sales constitute roughly 60% of total sales in developed markets, reducing prescription volume but increasing overall accessibility and market penetration.

3. What safety concerns impact the market for sumatriptan?
   Risks of cardiovascular events limit use among certain patient populations, affecting overall market size.

4. Are there new developments in migraine treatments related to sumatriptan?
   Yes, innovative delivery methods (nasal spray, auto-injectors) and new triptan compounds are in development, potentially expanding treatment options.

5. What emerging markets present growth opportunities for both drugs?
   Countries in Asia-Pacific and Latin America are experiencing increased healthcare spending, infrastructure development, and demand for migraine and pain therapies.

---

References

[1] World Health Organization. (2022). Migraine Fact Sheet.
[2] Statista. (2022). Global NSAID market size.
[3] U.S. Food and Drug Administration. (2021). New formulations of migraine medications.
[4] IQVIA. (2022). OTC pain medication sales report.
[5] MarketWatch. (2021). Sumatriptan patent expiration impact analysis.
[6] FDA. (2020). NSAIDs safety communication.